Pharming Group reports interim financial results for the first nine months of 2018
Pharming Group N.V. presents its (unaudited) interim financial report for the first nine months and the third quarter ended 30 September 2018.
Compared with the first nine months of 2017 (on a like-for-like basis):
- Product revenues up 74% to €97.7 million, operating profit up 144% to €31.0 million, net profit up 131% to 11.7 million
Compared with the last quarter ended 30 June 2018:
- Product revenues up 30% to €38.6 million, operating profit up 82% to €14.7 million, net profit up 77% to €5.4 million
Cash increased to €72.2 million (after €7.5m repayment of debt) to invest in key growth drivers
“I am pleased to report very good results indeed today in a period of intense competition. The revenue and profit performance reinforces the success of our in-market strategy for RUCONEST®.”- Sijmen de Vries - CEO